Celyad Oncology announced that its CEO Georges Rawadi has decided to step down, effective as December 1, 2023. Georges has taken this decision for personal reasons. Michel Lussier will take over the CEO responsibilities ad interim.

Michel is co-founder and member of the board of Directors of Celyad Oncology. The company?s primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments.